Skip to main content Skip to navigation
Menu
Access myPennMedicine
RSS Feed

News Releases

Browse By:

Apply Filter
  • Presby

    Penn Presbyterian Medical Center Earns Commission on Cancer’s Outstanding Achievement Award

    June 26, 2018
    The American College of Surgeons Commission on Cancer (CoC) has granted a three-year accreditation and its highest honor, the Outstanding Achievement Award, to the Abramson Cancer Center at Penn Presbyterian Medical Center (PPMC). To earn the accreditation, a cancer program must meet or exceed the CoC quality care standards, be evaluated every three years through a survey process, and maintain levels of excellence in the delivery of comprehensive, patient-centered care.
  • Telemedicine

    Using Telemedicine to Bring Genetic Counseling to Community Cancer Care

    May 30, 2018
    PHILADELPHIA – Genetic counseling for cancer patients has become standard of care at academic medical centers, but patients cared for at community-based medical practices across the United States may not have access to these resources.

  • Penn-led Trial Shows AZEDRA Can Be Effective, Safe for Treatment of Rare Neuroendocrine Tumors

    May 29, 2018
    A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania.

  • Penn Medicine at the 2018 American Society of Clinical Oncology Annual Meeting June 1-5, Chicago

    May 29, 2018
    Experts from the Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in cancer research and treatment at ASCO’s Annual Meeting in Chicago from June 1-5. Watch this space for press releases as embargoes lift during the meeting.
  • “Icebreaker” Protein

    “Icebreaker” Protein Opens Genome for T cell Development, Penn Researchers Find

    February 20, 2018
    Study provides new view of immune cell identity, which can be harnessed to fight cancer, autoimmune disorders, and infectious diseases. Researchers in the Perelman School of Medicine at the University of Pennsylvania, describe this week in Immunity the role of a transcription factor called TCF-1 in targeting the condensed chromatin and regulating the availability of genome sequences in T-cell development.

  • Cabozantinib Shows Promise as First Line Treatment for Differentiated Thyroid Cancer

    February 13, 2018
    “Our trial shows that cabozantinib is an active agent for patients with RAI-refractory thyroid cancer and may be able to significantly improve the care of patients who are at this advanced stage of their disease,” said the study’s lead author Marcia S. Brose, MD PhD, an associate professor of Otorhinolaryngology: Head and Neck Surgery and director of the Center for Rare Cancers and Personalized Therapy at Penn.

  • Funding to Lead Team-Based Investigation of Gynecologic Cancer Therapies

    February 08, 2018
    Using de-identified patient data, the Dr. E. John Wherry's team will examine how individuals vary in their immune responses to different anti-cancer therapies. As part of this process, the researchers will scrutinize terabytes of data, including information on patients’ genomes, imaging studies, and medical and medication records, among other data.
  • gper-stain

    Penn Researchers Identify New Treatment Target for Melanoma

    January 16, 2018
    Melanoma is the deadliest form of skin cancer, despite accounting for only about one percent of skin cancers overall. Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma.

  • High Out-of-Pocket Costs May Place Oral Cancer Medications Out of Reach

    December 21, 2017
    Sticker shock may be leading many insured Americans with cancer to forego treatment with a wide range of oral cancer drugs, suggests a study published online this week in the Journal of Clinical Oncology.

  • Penn Medicine | Virtua Strategic Alliance Brings First Proton Therapy to South Jersey

    December 14, 2017
    Cancer care in South Jersey is about to enter a new era. Penn Medicine, in partnership with Virtua, announced plans to build a new proton facility on the campus of Virtua’s acute care hospital, Virtua Voorhees. The new $35 million center, which will allow cancer patients to undergo cutting edge proton therapy in single-room treatments, is expected to be completed by 2020.
Share This Page:
Post Tweet Share